Nine Square Therapeutics
Even promising biotech ventures with significant early funding can fail due to internal funding disputes and liquidity issues, highlighting the critical need for stable financial backing.
Nine Square Therapeutics was a Biotechnology and Pharmaceutical startup founded in 2020 in USA. It raised $55 million before collapsing in 2026 — 6 years of runway burned. IdeaProof's AI Failure Score: 0/100, driven by liquidity crisis, funding standstill. The shutdown affected employees, investors, and the broader Biotechnology and Pharmaceutical ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.
Why did Nine Square Therapeutics fail?
Nine Square Therapeutics failed in 2026 after 6 years of operation, losing $55 million in raised capital. The root cause was liquidity crisis, funding standstill. Key lesson: Even promising biotech ventures with significant early funding can fail due to internal funding disputes and liquidity issues, highlighting the critical need for stable financial backing.
2020 → 2026
$55 million
Biotechnology and Pharmaceutical
USA
Full Analysis
Nine Square Therapeutics, a biotechnology company founded in 2020, specialized in developing therapeutics for neurodegenerative diseases like Parkinson's. The company secured a $50 million Series A commitment from Apple Tree Partners and an additional $5 million grant from The Michael J. Fox Foundation. Despite its innovative computational-to-clinic platform and promising research, Nine Square Therapeutics filed for Chapter 11 bankruptcy on January 1, 2026. The primary cause was a severe liquidity crisis stemming from a funding standstill between its parent fund, Apple Tree Partners, and a primary limited partner. This internal dispute prevented the company from accessing necessary capital, leading to its downfall. The case underscores how even well-funded and scientifically advanced startups can collapse due to financial mismanagement or investor disagreements, regardless of their product potential.
Could This Failure Have Been Prevented?
IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Nine Square Therapeutics.